Results 181 to 190 of about 13,822,676 (240)

Oxadiazolone‐Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II‐Induced Vascular Contraction

open access: yesChemMedChem, Volume 21, Issue 17, 14 September 2026.
A novel series of candidate AT1 receptor antagonists based on oxadiazolone‐triazole scaffolds was designed and synthesized. Most compounds reduced angiotensin II‐induced vascular contraction in an initial biological screening, with compound 7f emerging as the most active derivative.
Larissa F. L. Ferreira   +5 more
wiley   +1 more source

Redefining Fluoroquinolone Antibiotics: Design and Synthesis of Degradable Fluoroquinolones to Reduce Environmental Persistence

open access: yesChemSusChem, Volume 19, Issue 17, 14 September 2026.
Redesign and development of an efficient, robust synthesis platform for environmentally improved fluoroquinolones. A significant challenge associated with antibiotics, and active pharmaceutical ingredients in general, is their intentional design for high stability, which promotes environmental persistence and contributes to the development of ...
Nathan Raeymackers   +6 more
wiley   +1 more source

A Novel Class of “Super‐Strained” Spiro Heterocycles: Gateway to 1‐Azaspiro[3.3]heptane Derivatives, and Biological Validation

open access: yesAngewandte Chemie, Volume 138, Issue 36, 1 September 2026.
A new class of “super‐strained” spiro heterocycles—spirocyclic 1‐azabicyclo[1.1.0]butanes—was synthesized via insertion of cyclobutane‐, oxetane‐, and azetidine‐containing sulfonium reagents into substituted azirines. The stability of this new class of compounds was studied.
Philipp Natho   +9 more
wiley   +2 more sources

In silico pipeline for GSK 3β inhibitor discovery in Alzheimer's disease using pharmacophore screening, docking, ADME filtering, and MD validation. [PDF]

open access: yesSci Rep
Elkotamy MS   +9 more
europepmc   +1 more source

Ligand-based pharmacophore modeling for the discovery of Na<sub>V</sub>1.7 inhibitors. [PDF]

open access: yesJ Comput Aided Mol Des
Piga M   +6 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, Volume 20, Issue 9, Page 2296-2322, September 2026.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy